(Janssen Pharmaceuticals, Inc./CNN/CNN Newsource) UNDATED (CNN/CNN Newsource/WKRC) – The FDA just approved a ketamine-derived nasal spray for helping to treat depression.
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone treatment for adults with major depressive disorder who have not responded to at least two other antidepressants.
Spravato was initially approved in 2019 for use alongside an oral antidepressant. The medication is related to ketamine, which can cause hallucinations and sedation, and therefore must be administered by a healthcare provider due to its potential adverse side effects.
According to Johnson & Johnson, approximately 21 million American adults suffer from major depressive disorder, with about one-third not responding to oral antidepressants alone.
The FDA just approved this ketamine-derived nasal spray for depression treatment
